Medical devices, healthcare technology and the business of care
PMA approval · P080020

GEL-ONE

Seikagaku Corp. · Decision date Mar 22, 2011

MEDTECHLEDGER EXPLANATIONP080020

What did the FDA approve?

FDA approved PMA P080020 for GEL-ONE on March 22, 2011. The applicant is Seikagaku Corp., and the product code is MOZ under the device category "Acid, hyaluronic, intraarticular." The stated indication is treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, NSAIDs, or analgesics such as acetaminophen.

The decision record is an original PMA approval, not a supplement or manufacturing notice. The source statement reports the approved indication only; it does not provide safety or effectiveness data, clinical trial details, or comparative performance information. No supplement type or supplement reason is listed.

FDA approval order statement

APPROVAL FOR THE GEL-ONE. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO NON-PHARMACOLOGIC THERAPY, NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) OR ANALGESICS, E.G., ACETAMINOPHEN.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Mar 22, 2011

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P080020
Regulatory pathway
Premarket approval application
Product code
MOZ
Decision code
APPR
Decision date
Mar 22, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P080020 received

    Application receipt date recorded by FDA.

  2. P080020 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P080020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080020

Product / regulatory recordCompanyPathwayDecision dateSource
GEL-ONEP080020/S055
Seikagaku Corp.PMA supplementApr 9, 2026FDA
GEL-ONEP080020/S057
Seikagaku Corp.PMA supplementAug 26, 2026FDA
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
SUPARTZ FXP980044/S068
Seikagaku Corp.PMA supplementAug 26, 2026FDA
Gelsyn-3P110005/S015
Ibsa Institut Biochimique SAPMA supplementJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Seikagaku Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records